A5039590450- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
- Airway Management and Intubation Techniques
- Cancer Diagnosis and Treatment
- Cardiovascular and exercise physiology
- Pediatric health and respiratory diseases
- Pharmacological Effects and Assays
- GDF15 and Related Biomarkers
- Global Cancer Incidence and Screening
- RNA modifications and cancer
- Neonatal Respiratory Health Research
- Pharmaceutical studies and practices
- Pharmaceutical Practices and Patient Outcomes
- Pulmonary Hypertension Research and Treatments
- Oral and gingival health research
- Lung Cancer Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Epigenetics and DNA Methylation
- Head and Neck Cancer Studies
- Radiopharmaceutical Chemistry and Applications
- School Health and Nursing Education
- Cystic Fibrosis Research Advances
American College of Chest Physicians
2014-2023
University of Pennsylvania
2017
Johns Hopkins University
2015
Saint Louis University
1989
Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related, inflammatory lung in which tumor necrosis factor-alpha overexpressed and has been suggested to play pathogenic role.To determine if infliximab, an anti-TNF-alpha antibody, results clinical benefit acceptable safety profile patients with moderate severe COPD.In multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study, subjects COPD received infliximab (3 mg/kg [n = 78] or 5...
Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator antiinflammatory effects. Replicate phase III trials of nebulized ensifentrine were conducted (ENHANCE-1 ENHANCE-2) to assess these effects in patients chronic obstructive pulmonary disease (COPD).
Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting beta2-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that placebo patients with moderate-to-severe COPD.Efficacy variables included 24-h trough FEV1 (mean 23 h 10 min 45 post-dose) at Week 12 (primary endpoint) after Day 1, percentage COPD days poor control (i.e., worsening symptoms). Safety was assessed by...
The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety umeclidinium (UMEC 62.5 μg 125 μg) added fluticasone furoate/vilanterol (FF/VI, 100/25 in chronic obstructive pulmonary disease (COPD).These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients randomized 1:1:1 treatment with once-daily blinded UMEC (delivering 55 μg), 113 or placebo (PBO) open-label FF/VI 92/22 μg; N = 1238 [intent-to-treat...
Rationale: CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction is associated with mucus accumulation and worsening chronic obstructive pulmonary disease (COPD) symptoms. Objectives: The aim of this phase IIb dose-finding study was to compare a potentiator, icenticaftor (QBW251), placebo in patients COPD bronchitis. Methods: Patients on triple therapy for at least three months were randomized six treatment arms (icenticaftor 450, 300, 150, 75, or 25 mg twice daily [b.i.d.])...
The adult respiratory distress syndrome (ARDS) is characterized by increased neutrophils and macrophages in bronchoalveolar lavage (BAL) fluid. Interleukin-1 (IL-1), an inflammatory mediator produced macrophages, has been shown to be chemo-tactic for stimulate lymphocyte activation proliferation of fibro-blasts. BAL was performed patients with ARDS, at high risk develop normal nonsmokers. After removal cells surfactant-complexed lipids centrifugation, the remaining supernatant concentrated...
Combinations of drugs with distinct and complementary mechanisms action may offer improved efficacy in the treatment chronic obstructive pulmonary disease (COPD). In two 12-week, double-blind, parallel-group studies, patients COPD were randomized 1:1:1 to once-daily umeclidinium (UMEC; 62.5 μg 125 μg) or placebo (PBO), added twice-daily fluticasone propionate/salmeterol (FP/SAL; 250/50 μg). both primary measure was trough forced expiratory volume 1 second (FEV1) at Day 85. Secondary...
Background: The combination of the inhaled muscarinic antagonist umeclidinium (UMEC) with long-acting β2-agonist vilanterol (VI) has been shown to provide significant improvements in lung function compared UMEC, VI, or placebo (PBO) patients chronic obstructive pulmonary disease (COPD). This study was specifically designed support these findings by assessing health-related quality life and symptomatic outcomes a similar population. Methods: 12-week multicenter, randomized, double-blind,...
The contribution of fluticasone furoate (FF) on lung function in the FF/vilanterol (VI) 100/25 μg combination has been demonstrated numerically, but not statistically.This multicentre, randomised, double-blind, controlled trial (GlaxoSmithKline study number 200820; clinicaltrials.gov NCT02105974) enrolled ≥40-year-old patients with chronic obstructive pulmonary disease (COPD), a ≥10-pack-year smoking history, post-bronchodilator forced expiratory volume 1 s (FEV1) 30-70% predicted value,...
Data on triple therapy (long-acting muscarinic antagonist [LAMA] + inhaled corticosteroid/long-acting beta2-agonist [ICS/LABA]) in symptomatic patients with chronic obstructive pulmonary disease (COPD) are limited. This post hoc analysis aimed to determine the efficacy of once-daily umeclidinium (UMEC; 62.5 μg) or placebo (PBO) plus open-label fixed-dose ICS/LABA COPD. were pooled from four randomized, double-blind, parallel-group trials (ClincalTrials.gov identifiers: NCT01772134,...
Long-acting bronchodilators including muscarinic antagonists are central to the management of patients with COPD. The Glycopyrrolate Effect on syMptoms and lung function (GEM2) study assessed efficacy safety twice-daily glycopyrrolate 15.6 μg in moderate-to-severe airflow limitation. This 12-week multicenter, double-blind randomized (1:1) twice daily (b.i.d.) or placebo both delivered via NeohalerTM device. primary objective was superiority compared for forced expiratory volume 1 second...
Although no nebulized, dual mechanism, long-acting bronchodilator is currently marketed, with the approval of once-daily muscarinic antagonist (LAMA) revefenacinefenacin, it theoretically possible to deliver a LAMA and beta2-agonist via standard jet nebulizer. The primary secondary objectives our study were characterize safety profile revefenacin administered sequentially before or in combination formoterol, nebulizer patients moderate very severe chronic obstructive pulmonary disease...
Purpose: This study investigated the efficacy, safety, and pharmacokinetics of inhaled corticosteroid/long-acting β 2 -agonist fixed-dose combination budesonide/formoterol fumarate (BFF) metered dose inhaler (MDI), compared with monocomponents budesonide (BD) MDI formoterol (FF) MDI, in patients moderate-to-severe COPD. Materials methods: In this Phase IIb, randomized, double-blind, four-period, five-treatment, incomplete-block, crossover (NCT02196077), all received BFF 320/9.6 μg FF 9.6 μg,...
BackgroundSmoking is the major risk factor for chronic obstructive pulmonary disease (COPD). In IMPACT, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy significantly reduced moderate/severe exacerbation rates and improved lung function health status versus FF/VI or UMEC/VI in COPD patients. This post hoc analysis investigated trial outcomes by smoking status.MethodsIMPACT was a double-blind, 52-week trial. Patients aged ≥40 years with symptomatic ≥1...
<b>Objective:</b> To assess once-daily (OD) long-acting muscarinic antagonist umeclidinium (UMEC) +inhaled corticosteroid/long-acting β<sub>2</sub>-agonist (ICS/LABA) or placebo (PBO) +ICS/LABA in GOLD D patients with COPD (symptomatic high future exacerbation risk). <b>Methods:</b> Pooled data from 4 randomised, double-blind trials were analysed post hoc<i>.</i> Patients used open-label fluticasone furoate/vilanterol 100/25mcg propionate/salmeterol 250/50mcg for wks before randomisation to...
Background Inhaler technique errors are common in chronic obstructive pulmonary disease (COPD) treatment, potentially leading to poor management. Our pooled analysis approach assessed correct use and ease-of-use of a placebo ELLIPTA dry-powder inhaler (DPI) patients with COPD. Methods Adults COPD from open-label/non-blinded studies evaluating DPI reporting outcomes (based on the patient information leaflet [PIL]) and/or were included. Correct ease-of at study end primary secondary endpoints,...
Background: Indacaterol 75 µg once daily is a long-acting β 2 agonist approved for maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study was to evaluate patients' perception onset effect single dose. Methods: In double-blind, crossover, Phase IV study, 40 were randomized receive dose indacaterol or placebo via dry powder inhaler device. primary variable time until patient’s effect, using simple self-administered...